Key statistics
As of last trade, Formycon AG (FYBX:GER) traded at 47.30, 25.63% above the 52 week low of 37.65 set on Apr 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 47.20 |
---|---|
High | 47.75 |
Low | 45.15 |
Bid | 47.05 |
Offer | 47.65 |
Previous close | 46.50 |
Average volume | 5.51k |
---|---|
Shares outstanding | 17.66m |
Free float | 11.19m |
P/E (TTM) | 11.63 |
Market cap | 821.05m EUR |
EPS (TTM) | 4.00 EUR |
Data delayed at least 15 minutes, as of Nov 22 2024 11:57 GMT.
More ▼
- EQS-News: Formycon applies for admission to the Prime Standard of the Frankfurt Stock Exchange
- EQS-News: Formycon published results of analytical similarity study of biosimilar candidate FYB206 and Keytruda® in peer-reviewed journal Drugs in R&D
- Original-Research: Formycon AG (von First Berlin Equity Research GmbH): Buy
- EQS-News: Formycon and Fresenius Kabi receive FDA approval for FYB202/ OtulfiTM (ustekinumab-aauz)
- EQS-Adhoc: FDA grants approval for Stelara® Biosimilar FYB202/OtulfiTM (ustekinumab-aauz)
- EQS-News: Formycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases
More ▼